Lateral Femoral Cutaneous Nerve Block (LFCN) in ACL Reconstruction With MacFL-type Lateral Tenodesis (RECUP- NCLC)

The goal of this randomized clinical trial is to evaluate whether adding an ultrasound-guided lateral femoral cutaneous nerve (LFCN) block to a standard regional analgesia protocol improves postoperative recovery in patients undergoing anterior cruciate ligament (ACL) reconstruction combined with MacIntosh-type lateral extra-articular tenodesis.

The main question the study aims to answer is whether adding an LFCN block to an adductor canal block (ACB) and an iPACK block improves the quality of postoperative recovery, as measured by the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery.

The study will also assess:

  • Preservation of quadriceps function, assessed by the ability to perform a straight leg raise (SLR).
  • Postoperative pain at the lateral thigh graft harvest site and knee, at rest and during mobilization.
  • Cumulative oral opioid consumption during the first 48 hours after surgery.
  • Incidence of postoperative nausea and vomiting (PONV).
  • Time to first postoperative ambulation.
  • Patient satisfaction with analgesic management.

Adverse events and complications related to regional anesthesia, including sensory disturbances, hematoma, infection, and signs of local anesthetic systemic toxicity.

Participants will be randomly assigned in a 1:1 ratio to one of two treatment groups. All participants will undergo ACL reconstruction combined with MacIntosh-type lateral extra-articular tenodesis and will receive an ACB and an iPACK block. Participants in the experimental group will additionally receive an ultrasound-guided LFCN block.

Postoperative assessments will include QoR-15, pain scores, opioid consumption, PONV, quadriceps function, ambulation, patient satisfaction, and safety assessments during the first 48 hours after surgery and at 1 month. The primary outcome will compare the QoR-15 score at 24 hours between the two groups, with an 8-point difference considered clinically meaningful.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

108

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult patients aged 18 to 60 years;
  • Presenting a primary anterior cruciate ligament (ACL) tear;
  • Scheduled for ACL reconstruction associated with MacIntosh-type lateral extra-articular tenodesis (or equivalent technical variant using an iliotibial band 'ITB' graft);
  • Surgery to be performed under general anesthesia;
  • Planned management in outpatient surgery or short-stay hospitalization after the operation;
  • Understanding the validated French version of the QoR-15 questionnaire;
  • Having given their informed consent to participate in the study;
  • Patients affiliated with or benefiting from a social security scheme.

Exclusion Criteria:

  • Patients having allergy to local anesthetics or a contraindication to peripheral nerve blocks;
  • Patients having neuropathy of the lower limbs;
  • Patients having coagulation disorders or on major anticoagulation;
  • Patients suffering from chronic pain that requires more than 30 mg morphine-equivalents per day;
  • Patients undergoing revision ACL reconstruction;
  • Patients with pre-existing hypoesthesia of the lateral thigh (e.g. known meralgia paresthetica);
  • Patients unable to complete the questionnaires or expressing refusal to participate;
  • Pregnant women, women of childbearing age without effective contraception), or women breastfeeding;
  • Protected adults under guardianship, curatorship or other legal protection, deprived of liberty or under guardianship or curatorship, or unable to give consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ACB + iPACK + LFCN Block

Participants will undergo anterior cruciate ligament reconstruction combined with MacIntosh-type lateral extra-articular tenodesis. They will receive an adductor canal block (ACB) and an iPACK block as the standard regional analgesia protocol, with the addition of an ultrasound-guided lateral femoral cutaneous nerve (LFCN) block.

Ultrasound-guided adductor canal block administered as part of the standard regional analgesia protocol for ACL reconstruction with MacIntosh-type lateral extra-articular tenodesis.

Ultrasound-guided iPACK block (infiltration between the popliteal artery and the posterior capsule of the knee) administered as part of the standard regional analgesia protocol.

Ultrasound-guided lateral femoral cutaneous nerve (LFCN) block administered in addition to the adductor canal block and iPACK block in the experimental arm.

Active Comparator: ACB + iPACK

Participants will undergo anterior cruciate ligament reconstruction combined with MacIntosh-type lateral extra-articular tenodesis. They will receive an adductor canal block (ACB) and an iPACK block without an additional lateral femoral cutaneous nerve (LFCN) block.

Ultrasound-guided adductor canal block administered as part of the standard regional analgesia protocol for ACL reconstruction with MacIntosh-type lateral extra-articular tenodesis.

Ultrasound-guided iPACK block (infiltration between the popliteal artery and the posterior capsule of the knee) administered as part of the standard regional analgesia protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Recovery (QoR-15) Score
Time Frame: 24 hours after surgery

The quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 score ranges from 0 to 150, with higher scores indicating better quality of recovery. The score will be assessed preoperatively before administration of regional anesthesia and again 24 hours after surgery. The primary analysis will compare the QoR-15 score at 24 hours between the experimental and active comparator groups. An 8-point difference between groups is considered the minimal clinically important difference.

24 hours after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Preservation of Quadriceps Function
Time Frame: 24 hours after surgery

Quadriceps function will be assessed by the ability to perform a straight leg raise (SLR) at 24 hours postoperatively.

24 hours after surgery
Postoperative Lateral Thigh and Knee Pain
Time Frame: 6, 24, and 48 hours after surgery

Pain intensity at the lateral thigh graft harvest site and knee will be assessed at rest and during mobilization using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst pain imaginable).

6, 24, and 48 hours after surgery
Cumulative Postoperative Opioid Consumption
Time Frame: Day 0, Day 1, and Day 2 after surgery

Total oral opioid consumption will be recorded and converted to morphine milligram equivalents (MME).

Day 0, Day 1, and Day 2 after surgery
Postoperative Nausea and Vomiting
Time Frame: Day 0, Day 1, and Day 2 after surgery

The incidence of postoperative nausea and vomiting (PONV) will be recorded during the postoperative period.

Day 0, Day 1, and Day 2 after surgery
Time to First Postoperative Ambulation
Time Frame: Day 1 after surgery

Time from surgery to first postoperative ambulation will be recorded in hours.

Day 1 after surgery
Patient Satisfaction With Analgesic Management
Time Frame: Day 1 and Day 2 after surgery

Patient satisfaction with postoperative analgesic management will be assessed using a 5-point Likert scale.

Day 1 and Day 2 after surgery
Safety and Adverse Events Related to Regional Anesthesia
Time Frame: Day 1 and 1 month after surgery

Adverse events and complications potentially related to regional anesthesia will be recorded, including hypoesthesia or paresthesia of the lateral thigh, abnormal sensory disturbances, hematoma at the LFCN block site, infection, and signs of local anesthetic systemic toxicity.

Day 1 and 1 month after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yoann ELMALEH, Hôpital Privé Claude Galien

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2027

Study Registration Dates

First Submitted

November 3, 2026

First Submitted That Met QC Criteria

November 3, 2026

First Posted (Actual)

November 9, 2026

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe